1. View quote in context »
    The trial will commence following communications with regulatory authorities. rFIXFc has received orphan medicinal product designation for the treatment of hemophilia B from both the European (EMEA) and US (FDA) authorities. "rFIXFc is an example of Biogen Idec's commitment to developing innovative therapies to address significant unmet medical needs. The rFIXFc program has the potential to improve the lives of individuals with hemophilia B and we are excited about advancing the program" said Glenn Pierce, Vice President and Chief Medical Officer of Biogen Idec's hemophilia therapeutic area. Full Article at Street Insider
    rFIXFc is an example of Biogen Idec's commitment to developing innovative therapies to address significant unmet medical needs. The rFIXFc program has the potential to improve the lives of individuals with hemophilia B and we are excited about advancing the program
    SOURCE: Street Insider 1 month ago